Evidence Hub

Formulation and evaluation of migrarelief herbal nasal gel for migraine management

Harshada Komarol, Pratik Londhe, Muskan N Malik, Aditi Mane, Snehalata S Mali, Gauri G Bhamare

International Journal of Pharmacy and Pharmaceutical Science, 2026

Abstract

Migraine is a chronic neurological disorder characterized by recurrent headaches and associated symptoms that significantly impair daily functioning. Conventional therapies, though effective, are often limited by systemic side effects and poor patient compliance, creating a need for safer and more efficient alternatives. The present study reports the development and evaluation of MigraRelief, a novel herbal in‑situ nasal mucoadhesive gel formulated with extracts of Withania somnifera (Ashwagandha) and Bacopa monnieri (Brahmi). Poloxamer 407 was employed as a thermosensitive gelling agent to achieve sol‑to‑gel transition at physiological temperature, while Carbopol 934P imparted mucoadhesive strength to prolong nasal residence time. Supporting excipients ensured solubility, stability, and pH compatibility. The formulation was systematically evaluated for physicochemical properties, gelation temperature, viscosity, pH, drug content, mucoadhesive strength, in‑vitro release, and ex‑vivo permeation across goat nasal mucosa. The optimized gel exhibited gelation at 34°C, strong mucoadhesion, and sustained drug release for up to eight hours, following Higuchi kinetics. Stability studies under ICH guidelines confirmed acceptable shelf‑life. Overall, MigraRelief demonstrates promising potential as a safe and effective herbal alternative for migraine management, combining rapid onset of action with prolonged therapeutic effect, and warrants further in‑vivo and clinical evaluation.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free